ArticleNature2025
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- An immuno-chemotherapeutic bone scaffold for tumor eradication and bone regeneration in drug-resistant osteosarcoma.Bioactive materials · 2026Article
- Dendritic Cells in the Immunoregulation of Myocardial Infarction: Mechanisms and Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer.Signal transduction and targeted therapy · 2026Review
- Herpes simplex virus type 1 interferes with signal transducer and activator of transcription 3 expression in infected mature dendritic cells.The Journal of general virology · 2026Article
- Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.Journal of medicinal chemistry · 2026Article
- Respiratory viruses activate autophagy via the IFN-STAT1/STAT5B-SOCS1 axis.PLoS pathogens · 2026Article
- Fate Bifurcation of Cellular Senescence: Dynamic Regulation from Tumor Suppression to Recurrence Risk.Cells · 2026Review
- Amino Acids as Targets for Immunotherapy against Solid Tumors.Cell biochemistry and biophysics · 2026Review
- Circadian rhythms and lung cancer biology and immunotherapy: Emerging opportunities and challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention.Molecular cancer · 2026Review
- Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Endoplasmic reticulum stress in antitumor immunity and immunotherapy resistance: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader.Journal of medicinal chemistry · 2026Article
- Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironmentMaterials today. Bio · 2026Article
- ILC2-derived IL-9 activates regulatory T cells to facilitate post-myocardial infarction repair.Cell communication and signaling : CCS · 2026Article
- Pentose phosphate pathway fuels cGAS-STING signalling to boost function of intratumoral conventional dendritic cells.Nature communications · 2026Article
- miR-500a-3p negatively regulates SOCS2 and participates in the proliferation, glycolysis, and apoptosis of HCC cells via the JAK2/STAT5 pathway.Journal of applied biomedicine · 2026Article
- DLX2 marks an immunosuppressive dendritic-cell program that reshapes cytotoxic immunity and marks a tolerogenic microenvironment in lung adenocarcinoma.Discover oncology · 2026Article
- Targeting inflammatory microenvironments: overcoming therapy resistance and immunosuppression.Molecular cancer · 2026Review
- Targeting STAT3 Promotes Tumor Cell Death and Enhances T-Cell Activity in HPV16-Positive Cancer.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Jiajia ZhouDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Kole TisonDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0002-4076-6380
Haibin ZhouDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Longchuan BaiDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Ranjan Kumar AcharyyaDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Donna McEachernDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Hoda MetwallyDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Yu WangDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Michael PitterDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0002-1183-4217
Jae Eun ChoiDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Linda VatanDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Peng LiaoDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0002-8409-5574
Jiali YuDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Heng LinDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Long JiangCenter of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Shuang WeiDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Xue GaoDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0009-0006-4127-3808
Sara GroveDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Abhijit ParoliaDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Marcin CieslikDepartment of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA.
Ilona KryczekDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0002-3130-2533
Michael D GreenCenter of Excellence for Cancer Immunology and Immunotherapy, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Jian-Xin LinLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-5849-9412
Arul M ChinnaiyanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.ORCID 0000-0001-9282-3415
Warren J LeonardLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5740-7448
Shaomeng WangDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. shaomeng@umich.edu.ORCID 0000-0002-8782-6950
Weiping ZouDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. wzou@umich.edu.ORCID 0000-0001-7952-3549
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Gary D Luker · 1988 to 2026
$178.2MSmall-molecule STAT3 degradersR01CA244509 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WANG, SHAOMENG · 2020 to 2024
$3.0MMDSCs in Ovarian CancerR01CA193136 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2015 to 2019
$2.5MMemory T Cells in the Tumor MicroenvironmentR01CA152470 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2011 to 2015
$1.9MHuman Tregs in Ovarian CancerR01CA099985 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2006 to 2014
$1.8MNovel immunosupressive macrophages in human ovarian tumorR01CA123088 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZOU, WEIPING · 2007 to 2011
$1.4MNCI NIH HHS P30 CA046592NCI NIH HHS R01 CA099985NCI NIH HHS R01 CA123088NCI NIH HHS R01 CA152470NCI NIH HHS R01 CA193136NCI NIH HHS R01 CA244509
Abstract
Immune checkpoint blockade (ICB) has transformed cancer therapy
Indexed as
Dendritic CellsNeoplasmsSTAT3 Transcription FactorSTAT5 Transcription FactorAnimalsCell Line, TumorFemaleHumansImmune Checkpoint InhibitorsImmunotherapyJanus Kinase 2MaleMiceMice, Inbred C57BLProteolysisSignal TransductionImmune Checkpoint InhibitorsJanus Kinase 2Stat3 protein, mouseSTAT3 Transcription FactorSTAT5 Transcription Factor
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.